Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Zhuoye Xie"'
Autor:
Qingyun Zhu, Qiuzi Dai, Lei Zhao, Chang Zheng, Qinyuan Li, Zigao Yuan, Lulu Li, Zhuoye Xie, Zixuan Qiu, Wenjun Huang, Guowen Liu, Xuyu Zu, Bizhu Chu, Yuyang Jiang
Publikováno v:
Cell Death and Disease, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract PARP inhibitors and HDAC inhibitors have been approved for the clinical treatment of malignancies, but acquired resistance of or limited effects on solid tumors with a single agent remain as challenges. Bioinformatics analyses and a combinat
Externí odkaz:
https://doaj.org/article/130f5bf9dcba44a29bcf23396af299cf
Autor:
Yingying Shen, Qingyun Zhu, Maoyu Xiao, Liyang Yin, Wenjie Feng, Jianbo Feng, Jun He, Pei Li, Xiguang Chen, Wenjun Ding, Jing Zhong, Zhaolin Zeng, Zhuoye Xie, Jianghua Liu, Xuyu Zu
Publikováno v:
Cell Death and Disease, Vol 13, Iss 8, Pp 1-14 (2022)
Abstract Triple-negative breast cancer (TNBC), an aggressive histological subtype of breast cancer, exhibits a high risk of early recurrence rate and a poor prognosis, and it is primarily associated with the abundance of cancer stem cells (CSCs). At
Externí odkaz:
https://doaj.org/article/332a623b5ded452fa46327bd86d79fb9
Autor:
Qingyun Zhu, Qiuzi Dai, Chang Zheng, Lei Zhao, Qinyuan Li, Zigao Yuan, Lulu Li, Zhuoye Xie, Zixuan Qiu, Guowen Liu, Xuyu Zu, Bizhu Chu, Yu Jiang
Background and Purpose: PARP and HDAC inhibitors are approved for the clinical treatment of malignancies, but acquired resistance or limited effects on solid tumors with single-agent present challenges. Therefore, there is an urgent need to design an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::911373c54d59031964c6dc8406988c2e
https://doi.org/10.22541/au.167369414.48398608/v1
https://doi.org/10.22541/au.167369414.48398608/v1
